<DOC>
	<DOCNO>NCT01554826</DOCNO>
	<brief_summary>The clinical trial design evaluate immunogenicity safety pediatric Inactivated influenza vaccine ( Split Virion ) ( 0.25ml formulation ) Hualan administer infant age 6 month 36 month .</brief_summary>
	<brief_title>Clinical Trial Inactivated Influenza Vaccine ( 0.25ml Formulation Pediatric Use )</brief_title>
	<detailed_description>The clinical trial design randomize double-blind . Participants include 810 person ( 540 person test group 270 person control group ) . Healthy 6-36 month infant select , whose guardian volunteer sign informed consent . Subjects select accord inclusion exclusion criterion . Every subject accept 30min 's observation hospital vaccination receive periodic follow-up till fourth week boost vaccination . Blood subject collect third week boost vaccination analysis immunogenicity . During test , adverse reaction detail information report SFDA status blind every month . Unblinding conducted completion follow-up subject .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Infants age 636 month , guardian understand sign inform consent Healthy infant inquire illness history , physical examination clinical judgment complies vaccination product Be able comply requirement clinical trial protocol Have history vaccination within past 6 month vaccination product within late 1 week Axillary temperature ≤37.0℃ . 1 . Exclusion criterion primary vaccination : History vaccine immunoglobulin inoculation within 2 week History eclampsia , epilepsy , encephalopathy mental disease family disease History vaccination allergy allergy drug food ( egg ) Known suspect immunological function defect , include immunosuppressant therapy ( radiotherapy , chemotherapy , corticosteroid hormone , antimetabolite , cytotoxic drug ) , genetic defect ( favism ) , HIV infection reason Congenital malformation , maldevelopment serious chronic disease ( Down syndrome , diabetes , sickle cell anemia neurologic disease ) Acute chronic contagion , active infection ( history fever within past 3 day ( axillary temperature ≥38.0℃ ) acute disease need application antibiotic antivirus treatment whole body ) Organic diseases liver , kidney , serious cardiovascular disease Malignancy ( tumor ) , serious asthma Thrombopenia coagulopathy may cause contraindication intramuscular injection Any condition result absence removal spleen Hypertension ( include high blood pressure 150mmHg low blood pressure 100mmHg control drug ) Participating another clinical trial condition , judgment investigator , may affect trial assessment . 2 . Exclusion criterion boost vaccination : Any condition `` Exclusion criterion '' first injection inclusion Adverse reaction level 3 within 72 hour first vaccination ; Serious adverse reaction casual relationship first inoculation test vaccine Subjects willing inoculate quit Axillary temperature ≥37℃ immunization Reasons conduct inoculation , judgment investigator .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>36 Months</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Pediatric influenza vaccine</keyword>
</DOC>